DiaMedica Therapeutics Statistics
Total Valuation
DMAC has a market cap or net worth of $443.81 million. The enterprise value is $400.49 million.
| Market Cap | 443.81M |
| Enterprise Value | 400.49M |
Important Dates
The next estimated earnings date is Wednesday, November 11, 2026, after market close.
| Earnings Date | Nov 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
DMAC has 53.93 million shares outstanding. The number of shares has increased by 22.41% in one year.
| Current Share Class | 53.93M |
| Shares Outstanding | 53.93M |
| Shares Change (YoY) | +22.41% |
| Shares Change (QoQ) | +0.19% |
| Owned by Insiders (%) | 46.69% |
| Owned by Institutions (%) | 20.49% |
| Float | 25.30M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 11.58 |
| P/TBV Ratio | 11.58 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.72, with a Debt / Equity ratio of 0.00.
| Current Ratio | 6.72 |
| Quick Ratio | 6.63 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -114.62% and return on invested capital (ROIC) is -74.31%.
| Return on Equity (ROE) | -114.62% |
| Return on Assets (ROA) | -64.12% |
| Return on Invested Capital (ROIC) | -74.31% |
| Return on Capital Employed (ROCE) | -102.13% |
| Weighted Average Cost of Capital (WACC) | 9.28% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.07M |
| Employee Count | 35 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, DMAC has paid $30,000 in taxes.
| Income Tax | 30,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +19.97% in the last 52 weeks. The beta is 0.91, so DMAC's price volatility has been similar to the market average.
| Beta (5Y) | 0.91 |
| 52-Week Price Change | +19.97% |
| 50-Day Moving Average | 6.89 |
| 200-Day Moving Average | 7.10 |
| Relative Strength Index (RSI) | 70.23 |
| Average Volume (20 Days) | 215,909 |
Short Selling Information
The latest short interest is 5.49 million, so 10.17% of the outstanding shares have been sold short.
| Short Interest | 5.49M |
| Short Previous Month | 5.39M |
| Short % of Shares Out | 10.17% |
| Short % of Float | 21.69% |
| Short Ratio (days to cover) | 41.24 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -39.23M |
| Pretax Income | -37.51M |
| Net Income | -37.54M |
| EBITDA | -39.17M |
| EBIT | -39.23M |
| Earnings Per Share (EPS) | -$0.72 |
Balance Sheet
The company has $43.50 million in cash and $185,000 in debt, with a net cash position of $43.32 million or $0.80 per share.
| Cash & Cash Equivalents | 43.50M |
| Total Debt | 185,000 |
| Net Cash | 43.32M |
| Net Cash Per Share | $0.80 |
| Equity (Book Value) | 38.34M |
| Book Value Per Share | 0.71 |
| Working Capital | 37.72M |
Cash Flow
In the last 12 months, operating cash flow was -$31.51 million and capital expenditures -$33,000, giving a free cash flow of -$31.54 million.
| Operating Cash Flow | -31.51M |
| Capital Expenditures | -33,000 |
| Depreciation & Amortization | 52,000 |
| Net Borrowing | -11,000 |
| Free Cash Flow | -31.54M |
| FCF Per Share | -$0.58 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
DMAC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -22.41% |
| Shareholder Yield | n/a |
| Earnings Yield | -8.46% |
| FCF Yield | -7.11% |
Analyst Forecast
The average price target for DMAC is $15.50, which is 88.34% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $15.50 |
| Price Target Difference | 88.34% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on November 15, 2018. It was a reverse split with a ratio of 1:20.
| Last Split Date | Nov 15, 2018 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |